Indole clubbed 2,4-thiazolidinedione linked 1,2,3-triazole as a potent antimalarial and antibacterial agent against drug-resistant strain and molecular modeling studies
© 2024 Deutsche Pharmazeutische Gesellschaft..
In the face of escalating challenges of microbial resistance strains, this study describes the design and synthesis of 5-({1-[(1H-1,2,3-triazol-4-yl)methyl]-1H-indol-3-yl}methylene)thiazolidine-2,4-dione derivatives, which have demonstrated significant antimicrobial properties. Compared with the minimum inhibitory concentrations (MIC) values of ciprofloxacin on the respective strains, compounds 5a, 5d, 5g, 5l, and 5m exhibited potent antibacterial activity with MIC values ranging from 16 to 25 µM. Almost all the synthesized compounds showed lower MIC compared to standards against vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus strains. Additionally, the majority of the synthesized compounds demonstrated remarkable antifungal activity, against Candida albicans and Aspergillus niger, as compared to nystatin, griseofulvin, and fluconazole. Furthermore, the majority of compounds exhibited notable inhibitory effects against the Plasmodium falciparum strain, having IC50 values ranging from 1.31 to 2.79 μM as compared to standard quinine (2.71 μM). Cytotoxicity evaluation of compounds 5a-q on SHSY-5Y cells at up to 100 μg/mL showed no adverse effects. Comparison with control groups highlights their noncytotoxic characteristics. Molecular docking confirmed compound binding to target active sites, with stable protein-ligand complexes displaying drug-like molecules. Molecular dynamics simulations revealed dynamic stability and interactions. Rigorous tests and molecular modeling unveil the effectiveness of the compounds against drug-resistant microbes, providing hope for new antimicrobial compounds with potential safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:357 |
|---|---|
| Enthalten in: |
Archiv der Pharmazie - 357(2024), 4 vom: 15. Apr., Seite e2300673 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Upadhyay, Dipti B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ardp.202300673 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367377233 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367377233 | ||
| 003 | DE-627 | ||
| 005 | 20240408232248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ardp.202300673 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM367377233 | ||
| 035 | |a (NLM)38247229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Upadhyay, Dipti B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Indole clubbed 2,4-thiazolidinedione linked 1,2,3-triazole as a potent antimalarial and antibacterial agent against drug-resistant strain and molecular modeling studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Deutsche Pharmazeutische Gesellschaft. | ||
| 520 | |a In the face of escalating challenges of microbial resistance strains, this study describes the design and synthesis of 5-({1-[(1H-1,2,3-triazol-4-yl)methyl]-1H-indol-3-yl}methylene)thiazolidine-2,4-dione derivatives, which have demonstrated significant antimicrobial properties. Compared with the minimum inhibitory concentrations (MIC) values of ciprofloxacin on the respective strains, compounds 5a, 5d, 5g, 5l, and 5m exhibited potent antibacterial activity with MIC values ranging from 16 to 25 µM. Almost all the synthesized compounds showed lower MIC compared to standards against vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus strains. Additionally, the majority of the synthesized compounds demonstrated remarkable antifungal activity, against Candida albicans and Aspergillus niger, as compared to nystatin, griseofulvin, and fluconazole. Furthermore, the majority of compounds exhibited notable inhibitory effects against the Plasmodium falciparum strain, having IC50 values ranging from 1.31 to 2.79 μM as compared to standard quinine (2.71 μM). Cytotoxicity evaluation of compounds 5a-q on SHSY-5Y cells at up to 100 μg/mL showed no adverse effects. Comparison with control groups highlights their noncytotoxic characteristics. Molecular docking confirmed compound binding to target active sites, with stable protein-ligand complexes displaying drug-like molecules. Molecular dynamics simulations revealed dynamic stability and interactions. Rigorous tests and molecular modeling unveil the effectiveness of the compounds against drug-resistant microbes, providing hope for new antimicrobial compounds with potential safety | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antimicrobial activity | |
| 650 | 4 | |a click reaction | |
| 650 | 4 | |a cytotoxicity | |
| 650 | 4 | |a molecular modeling | |
| 650 | 4 | |a resistance strains | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a 2,4-thiazolidinedione |2 NLM | |
| 650 | 7 | |a AA68LXK93C |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Thiazolidinediones |2 NLM | |
| 700 | 1 | |a Mokariya, Jaydeep A |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Paras J |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Subham G |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Anwesha |e verfasserin |4 aut | |
| 700 | 1 | |a Nandi, Arijit |e verfasserin |4 aut | |
| 700 | 1 | |a Nogales, Joaquina |e verfasserin |4 aut | |
| 700 | 1 | |a More, Nachiket |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Rajani, Dhanji P |e verfasserin |4 aut | |
| 700 | 1 | |a Narayan, Mahesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Jyotish |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Sourav |e verfasserin |4 aut | |
| 700 | 1 | |a Sahoo, Suban K |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Hitendra M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archiv der Pharmazie |d 1972 |g 357(2024), 4 vom: 15. Apr., Seite e2300673 |w (DE-627)NLM000013323 |x 1521-4184 |7 nnns |
| 773 | 1 | 8 | |g volume:357 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:e2300673 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ardp.202300673 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 357 |j 2024 |e 4 |b 15 |c 04 |h e2300673 | ||